A Phase 3 interventional study of Prevention of pneumococcal disease from 24 serotypes with the administration of Reinovax's PCV24 and PPSV23 in Pneumococcal Infectious Disease, sponsored by Reinovax Biologics Co., LTD. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Reinovax Biologics Co., LTD · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Pneumococcal Infections with a site in China — 6 open to participants now, 9 under way, 4 of them phase 3. Pneumococcal Infections · China.
Among the 36 studies in Pneumococcal Infections with a site in China, this one is the 10th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 in phase 3, and was the 37th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →6 of the 36 studies in Pneumococcal Infections with a site in China are open now. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
CanSino Biologics Inc. · Sites in China
Ages 6 wk+ · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 42 days–5 yrs · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 42 days–23 mo · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 6 wk–5 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 5 · Phase 3 9 · Phase 4 6
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,260 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 480 across the 33 interventional studies, 3,641 across the 3 observational. Of the 26 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 36 have an industry lead sponsor. The 10 most frequent:
Reinovax Biologics Co., LTD is the lead sponsor of 3 studies on the registry; none are open to participants now.
Reinovax Biologics Co., LTD has 3 studies filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumococcal Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600983CanSino Biologics Inc.Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | 2026-11-24 |
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Pneumococcal Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase III clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.The study's objective is to evaluate the safety and immunogenicity of PCV24. The trial is a multicenter, randomized, double-blind and active-controlled phase III clinical trial.
A Phase Ⅲ clinical trial of the 24-valent pneumococcal conjugate vaccine (PCV24) developed by Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older. The study's objective is to evaluate the safety and immunogenicity of PCV24. The active control vaccine is a 23-valent pneumococcal polysaccharide vaccine (PPSV23) produced by Merck \& Co.A total of 1,260 participants will be enrolled, including 756 participants aged 65-74 years, who will be randomized 1:1 to receive one dose of PCV24 or PPSV23, and 84 participants aged 75 years and older, who will be randomized 1:1 to receive one dose of PCV24 or PPSV23. In addition, 420 participants aged 18-64 years will receive one dose of PCV24.
Inclusion Criteria:
1)Aged 18 years and older, able to provide valid legal identification; 2)Capable of understanding the clinical trial procedures, voluntarily agreeing to participate, and signing the form; 3)Willing and able to comply with the requirements of the clinical trial protocol and to attend all scheduled visits; 4) Male participants and female participants of agreeing to use effective within 6 months after vaccination (effective contraceptive measures include: oral contraceptives, injectable or implanted contraceptives, sustained-release topical contraceptives, hormone patches, intrauterine device (IUD), sterilization, abstinence, and condoms (for males)); the rhythm method, coitus interruptus, and emergency contraception are not acceptable contraceptive measures; 5) Axillary temperature ≤37.0°C on the day of enrollment. Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
378 participants aged 65-74 years will be randomly assigned to receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
Biological: Prevention of pneumococcal disease from 24 serotypes with the administration of Reinovax's PCV24
378 participants aged 65-74 years will be randomly assigned to receive PPSV23. The route of administration is intramuscular injection into the lateral deltoid muscle of the upper arm. The immunization schedule is 1 dose.
Biological: PPSV23
42 participants aged 75 years and older will be randomly assigned to receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
Biological: Prevention of pneumococcal disease from 24 serotypes with the administration of Reinovax's PCV24
42 participants aged 75 years and older will be randomly assigned to receive PPSV23. The route of administration is intramuscular injection into the lateral deltoid muscle of the upper arm. The immunization schedule is 1 dose.
Biological: PPSV23
420 participants aged 18-64 years will receive Reinovax's PCV24. The route of administration is intramuscular injection into the deltoid muscle of the upper arm. The immunization schedule is 1 dose.
Biological: Prevention of pneumococcal disease from 24 serotypes with the administration of Reinovax's PCV24
Prevention of pneumococcal infection caused from 24 pneumococcal serotypes (1, 2, 3, 4 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) using a novel PCV24 prepared with Reinovax's non-toxic dual carrier protein system. Administration of one dose at 0.5 mL
One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and 33F polysaccharides.
Also known as: Pneumovax 23
Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).
The geometric mean titers (GMTs) of 24 vaccine serotype-specific MOPA antibodies at 0 days and 30 days after vaccination in participants aged 65 years and older, measured by the multiplexed opsonophagocytic assay (MOPA).
Time frame: 0~30 days after vaccination
Proportional participants with the MOPA titer rise of 4-fold or higher
The percentage of participants aged 65 years and older whose MOPA antibody titers show a 4-fold or greater increase from the pre-immunization baseline at 30 days after vaccination, for each of the 24 vaccine serotypes.
Time frame: 0~30 days after vaccination
Functional antibody titers measured by the multiplexed opsonophagocytic assay (MOPA).
The geometric mean titers (GMTs) of the 24 vaccine serotype-specific MOPA antibodies at 0 day and 30 days after vaccination in participants aged 18-64 years, measured by the multiplexed opsonophagocytic assay (MOPA).
Time frame: 0~30 days after vaccination
Incidence of adverse events
The incidence of any local and systemic adverse events occurring within 30 minutes after vaccination.
Time frame: 0-30 minutes after vaccination
Incidence of solicited adverse events
The incidence of solicited adverse events occurring within 7 days after vaccination.
Time frame: 0-7 days after vaccination
Incidence of unsolicited adverse events
The incidence of unsolicited adverse events occurring within 30 days after vaccination.
Time frame: 0-30 days after vaccination
Incidence of serious adverse events (SAE)
The incidence of serious adverse events (SAE) occurring within 6 months after vaccination.
Time frame: 0-6 months after vaccination
Seropositivity rate as measured using MOPA
The percentage of participants aged 65 years and older with MOPA antibody titers ≥1:8 for each of the 24 vaccine serotypes, detected by MOPA 30 days after immunization. Unit of measure: percentage of participants.
Time frame: 0~30 days after vaccination
Increase rate of as measured using MOPA
The percentage of participants aged 65 years and older whose MOPA antibody titer shows a 2-fold or greater increase from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.
Time frame: 0~30 days after vaccination
The geometric mean fold rise (GMFR) of MOPA antibody titers
The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific MOPA antibody titers from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 65 years and older.
Time frame: 0~30 days after vaccination
Seropositivity rate of IgG antibodies
The percentage of participants aged 65 years and older with IgG geometric mean concentration (GMC) ≥0.35 µg/mL for each of the 24 vaccine serotypes, detected by ELISA 30 days after immunization. Unit of measure: percentage of participants.
Time frame: 0~30 days after vaccination
Positive conversion rate of IgG antibodies
The percentage of participants aged 65 years and older whose IgG antibody concentration shows a 2-fold or greater increase (positive conversion) from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.
Time frame: 0~30 days after vaccination
The IgG geometric mean concentration (GMC) of each serotype
The geometric mean concentration (GMC) of 24 vaccine serotype-specific IgG antibodies detected by ELISA 30 days after immunization in participants aged 65 years and older.
Time frame: 0~30 days after vaccination
The geometric mean fold rise (GMFR) of IgG antibodies
The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific IgG antibody concentration from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 65 years and older.
Time frame: 0~30 days after vaccination
Seropositivity rate of multiplexed opsonophagocytic assay (MOPA) antibodies
The percentage of participants aged 18-64 years with MOPA antibody titer ≥1:8 for each of the 24 vaccine serotypes, detected by MOPA 30 days after immunization. Unit of measure: percentage of participants.
Time frame: 0~30 days after vaccination
Increase rate of multiplexed opsonophagocytic assay (MOPA) antibodies
The percentage of participants aged 18-64 years whose MOPA antibody titer shows a 2-fold or greater increase from the pre-immunization baseline (2-fold increase rate), and the percentage whose MOPA antibody titer shows a 4-fold or greater increase from the pre-immunization baseline (4-fold increase rate), at 30 days after immunization for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.
Time frame: 0~30 days after vaccination
The geometric mean fold rise (GMFR) of multiplexed opsonophagocytic assay (MOPA) antibodies
The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific MOPA antibody titer from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 18-64 years.
Time frame: 0~30 days after vaccination
Seropositivity rate of IgG antibodies
The percentage of participants aged 18-64 years with IgG antibody concentration ≥0.35 µg/mL for each of the 24 vaccine serotypes, detected by ELISA 30 days after immunization. Unit of measure: percentage of participants.
Time frame: 0~30 days after vaccination
Positive conversion rate of IgG antibodies
The percentage of participants aged 18-64 years whose IgG antibody concentration shows a 2-fold or greater increase (positive conversion) from the pre-immunization baseline at 30 days after immunization, for each of the 24 vaccine serotypes. Unit of measure: percentage of participants.
Time frame: 0~30 days after vaccination
The geometric mean concentration (GMC) of specific IgG antibodies
The geometric mean concentration (GMC) of 24 vaccine serotype-specific IgG antibodies detected by ELISA 30 days after immunization in participants aged 18-64 years.
Time frame: 0~30 days after vaccination
The geometric mean fold rise (GMFR) of specific IgG antibodies
The geometric mean fold rise (GMFR) in 24 vaccine serotype-specific IgG antibody concentration from the pre-immunization baseline to 30 days after immunization, and the ratio of GMFR between the vaccine group and the control group, in participants aged 18-64 years.
Time frame: 0~30 days after vaccination
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 11 months is close to that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Reinovax Biologics Co., LTD